Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported, Abbott has Agreements Regarding Change in Control (“Agreements”) with its named executive officers.…
Filed Nov 16, 2026Accepted Nov 13, 2026, 5:59 PM ESTCIK 1800Accession 0001104659-26-127273
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously reported, Abbott has Agreements Regarding Change in Control
(“Agreements”) with its named executive officers.
The Agreements provide that if Abbott gives notification of extension
before the Expiration Date (December 31, 2026), the Agreement’s term shall continue through the second anniversary of the Expiration
Date.
On November 11, 2026, Abbott notified the named executive officers,
other than Robert B. Ford, Abbott’s Chairman of the Board and Chief Executive Officer, that the term of the Agreements was extended
through December 31, 2028. Mr. Ford’s Agreement will expire on December 31, 2026.